| Literature DB >> 29588776 |
Darren Mylotte1,2, Ruben Lj Osnabrugge3, Giuseppe Martucci1, Ruediger Lange4, Arie Pieter Kappetein3, Nicolo Piazza1,4.
Abstract
Transcatheter aortic valve implantation (TAVI) is a novel therapeutic option for patients with severe symptomatic aortic stenosis (AS) at excessive or high surgical risk for conventional surgical aortic valve replacement. First commercialised in Europe in 2007, TAVI growth has been exponential among some Western European nations, though recent evidence suggests heterogeneous adoption of this new and expensive therapy. Herein, we review the evidence describing the utilisation of TAVI in Western Europe.Entities:
Keywords: Transcatheter aortic valve implantation; aortic stenosis
Year: 2014 PMID: 29588776 PMCID: PMC5808721 DOI: 10.15420/icr.2011.9.1.37
Source DB: PubMed Journal: Interv Cardiol ISSN: 1756-1485